This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Injectable Bulking Agents Market

Market Insights on Injectable Bulking Agents covering sales outlook, demand forecast & up-to-date key trends

Injectable Bulking Agents Market: Global Industry Analysis 2013 - 2017 and Opportunity Assessment; 2018 - 2028

Injectable bulking agents are truly effective for female stress urinary incontinence, new injectable bulking agents show promise with regard to efficacy and durability

Injectable bulking agents are synthetic materials (bovine collagen, or autologous substances) that collaborate with the body's (mainly urinary) regular framework to treat and anticipate unusual stress and urinary incontinence in the body. Injectable bulking agents are injected periurethrally to increase the tissue bulk and thereby increase resistance to the outflow of urine.

The bulking agent is injected into the per urethral tissue in the liquid form that then solidifies into a spongy material to bulk the urethral wall. Owing to the better and thorough understanding of the bio-chemical and physicochemical parameters by pharmaceutical scientists and better patient compliance, injectable bulking agents have gained considerable market share in the recent years. Injectable bulking agents are used as a preferred alternative over conventional surgical procedures and injectable drugs.

Injectable bulking agents treat a useless urethra, this procedure is a negligibly obtrusive technique for revising natural sphincter disorder that outcomes in stretch urinary incontinence yet is being performed less every now and again in current practice. Injectable bulking agents are made of manufactured materials, ox-like collagen, or autologous substances, which expand the urethral divider and increment urethral protection from the urinary stream.

Growing Utilization of Up-to-date Injectable Bulking Agents

The major driver in injectable bulking agents market is the wide adoption of agents especially in the female patients with lower risk. Injectable bulking agents market has seen a steady growth and there is rapid expansion in product pipelines. Also, over the past decade, more patient-friendly, better biomaterial and synthetic form has enhanced demand for injectable bulking agents market.

Its importance is recognized by both the academia and industry. Rising incidences of SUI (stress urinary incontinence) is also gaining traction. The lower efficacy and durability of bulking agents is balanced by low treatment morbidity with a favorable adverse event profile when compared to surgical management.

Injectable bulking agents can help the gathering of patients that is unfit or unwilling to experience surgery for incontinence. The persistent advancement of systems and materials gives a ground to more up-to-date building operators. In like manner, late research has indicated guarantee in the utilization of undifferentiated organisms in periurethral infusions.

Customize this Report

Let us know your requirement to get
100% FREE customization

Prominent Viability, Wellbeing, and Cost Adequacy of Direct Acting Injectable Bulking Agents

The lower viability and strength of bulking agents is adjusted by low treatment morbidity when contrasted with surgical administration. Infusion is regularly performed through a transurethral approach with endoscopic perception. Injectable bulking agents are more suited to low-to-direct volume SUI and diligent SUI after earlier against incontinence methods.

Geriatric patients with higher risk, or ineffectiveness to intrude on anticoagulation may profit by bulking if different interventions are not attainable. Different signs incorporate youth patients, who may want future pregnancy, or patients with a blend of SUI and deprived bladder emptying.

Regulatory Scenario with New Challenges

Various per urethral injectable bulking agents to treat urinary incontinence have been cleared by the FDA. Nonetheless, new products manufactured to date have not really met all the criteria of the perfect injectable bulking agents internationally. The main FDA-endorsed product was cross-linked collagen (e.g., Contigen).

The bulking agent was observed to be retained after some time and indications could repeat, requiring extra infusions. The manufacturing of Contigen was officially suspended in 2011. Other per urethral injectable bulking agents cleared by FDA for urinary incontinence incorporate carbon-covered dots (e.g., Durasphere), circular particles of calcium hydroxylapatite (CaHA) in a gel bearer (Coaptite, ethylene vinyl alcohol copolymer inserts (e.g., Tegress, in the past Uryx), and polydimethylsiloxane (silicone, macroplastique).

Injectable Bulking Agents Market Download Report Brochure

Sabyasachi Ghosh
Principal Consultant
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Regional Outlook

On the basis of regional presence, the global injectable bulking agents market is segmented into six key regions viz. North America, Latin America, Western Europe, Eastern Europe, and Asia Pacific excluding Japan, and Middle East & Africa. North America will continue to dominate the global market due to the availability of advanced technologies and more number of laboratory developed tests. Europe is expected to hold second large market share in the global injectable bulking agents market due to growing prevalence of urinary conditions and fecal incontinence.

Many non-FDA-approved injectable bulking agents are also in use in many developed and developing economies, e.g., dextranomer/hyaluronic acid with injection system is used to deliver the bulking agent in the outpatient clinic setting without need for endoscopy.

Key Market Vendors

Medium- and Large-Scale Manufacturers/Providers

  • Allergan Plc.
  • Advanced UroScience
  • CR Bard
  • Merz Aesthetics
  • Cogentix Medical
  • Q-Med
  • Coloplast Corp
  • Boston Scientific Corporation
  • AstraZeneca
  • Others
Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Research Methodology

The market sizing of injectable bulking agents will be done by the adoption data triangulation approach. Demand-side approach will be followed to assess the actual market size of injectable bulking agents. Secondary research will be done at the initial phase to identify the feasibility of the target products/technology categories and its respective segments, product and service offerings in end use facilities, adoption rate and future impact of new technologies.

Additionally, per capita consumption of among end users is tracked at a granular level to obtain the most accurate information. Each piece of information is eventually analyzed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side respondents such as laboratory managers, procurement managers, research supervisors at academic and research institutes, as well as key opinion leaders in addition to supply-side respondents such as equipment and drug manufacturers, custom solution and service providers who provide valuable insights on trends, research application of products and technologies, purchasing patterns, services offered and associated pricing. 

The report covers exhaustive analysis on

The report covers exhaustive analysis on

  • Injectable Bulking Agents Market by route of administration, end user and region
  • Regional level market analysis of North America, Latin America, Europe, Asia Pacific Excluding Japan, Japan, Middle East & Africa by route of administration, end use segments and country
  • Injectable Bulking Agents Market Dynamics & Opportunity Assessment
  • Historical Actual Market Size, 2013 - 2017
  • Injectable Bulking Agents Market Size & Forecast 2018-2028
  • Injectable Bulking Agents Current Trends/Issues/Challenges
  • Competition & Companies involved

The global market for Injectable bulking agents market is segmented on the basis of disease indication, end user and geography

By Disease Indication:

  • Stress Urinary Incontinence
  • Fecal Incontinence
  • Other Female Urinary Deficiency Disorders

By End Users:

  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • Others

Table of Content


Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables


Sabyasachi Ghosh
Principal Consultant
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts


Need specific information?

Request Customization

Explore Healthcare Insights

View Reports
Google translate

Injectable Bulking Agents Market